Yang Hui-yin, Li Jun, Yi Mao
302 Hospital of PLA, Beijing, China.
Zhongguo Zhong Yao Za Zhi. 2006 Aug;31(15):1277-80.
To study curative effect of chronical hepatitis B with treatment of integrative traditional Chinese and western medicine.
115 cases of HBeAg and/or HBVDNA positive chronical hepatitis B were randomly divided into two groups in control. The first group treated by traditional Chinese medicine (TCM)-Fufang Huangqi granule and the second treated by intergrative traditional Chinese and western medicine (ICWM)-Fufang Huangqi granule and lamivudine for at least 24 weeks.
The positive rate of HBVDNA at 12, 24 weeks, and the positive rate of HBeAg at 24 weeks in TCM are markedly lower than those of before treatment (P < 0.01). The positive rate of HBeAg and the positive rate of HBVDNA in ICWM are markedly lower than those of before treatment both at 12, 24 weeks (P < 0.01). The average values of HBVDNA are markly lower than before treatment in two groups at both 12,24 weeks (P < 0.01). At 12 weeks, the negative-turning rate of HBVDNA in the ICWM group is 79.17%, which shows significant difference in comparision with 40.00% in the TCM group (P < 0.01). The negative-turning rate of HBeAg in the ICWM group is 26.92%, which shows no significant difference in comparision with 32. 08% in the TCM group. At 24 weeks, the negative-turning rate of HBVDNA in the ICWM group is 85.71%, which shows significant difference in comparision with 50.00% in the TCM group (P < 0.01). The negative-turning rate of HBeAg in the ICWM group is 36.36%, which shows no significant difference in comparision with 28.57% in the TCM group. At 12 weeks,the total effective rate of the ICWM group is 96. 43%, which shows significant difference in comparision with 71.26% in the TCM group (P<0.01). At 24 weeks, the total effective rate of the ICWM group is 88. 00%, which shows significant difference in comparision with 67.61 % in the TCM group (P < 0.01). The average values of ALT and AST are markly improved than those of before treatment in two groups (P < 0.01). The average values of ALB is markly higher than before in TCM groups after 24 weeks treatment (P < 0.01).
Fufang Huangqi granule integrated with lamivudine possesses a better effect for counteracting the hepatitis B virus and improving the liver functioin than only itself.
探讨中西医结合治疗慢性乙型肝炎的疗效。
将115例HBeAg和/或HBVDNA阳性的慢性乙型肝炎患者随机分为两组。第一组采用中药（复方黄芪颗粒）治疗，第二组采用中西医结合（复方黄芪颗粒联合拉米夫定）治疗，疗程至少24周。
中药组治疗12周、24周时HBVDNA阳性率及24周时HBeAg阳性率均显著低于治疗前（P<0.01）。中西医结合组治疗12周、24周时HBeAg阳性率及HBVDNA阳性率均显著低于治疗前（P<0.01）。两组治疗12周、24周时HBVDNA平均值均显著低于治疗前（P<0.01）。治疗12周时，中西医结合组HBVDNA阴转率为79.17%，与中药组的40.00%相比有显著差异（P<0.01）。中西医结合组HBeAg阴转率为26.92%，与中药组的32.08%相比无显著差异。治疗24周时，中西医结合组HBVDNA阴转率为85.71%，与中药组的50.00%相比有显著差异（P<0.01）。中西医结合组HBeAg阴转率为36.36%，与中药组的28.57%相比无显著差异。治疗12周时，中西医结合组总有效率为96.43%，与中药组的71.26%相比有显著差异（P<0.01）。治疗24周时，中西医结合组总有效率为88.00%，与中药组的67.61%相比有显著差异（P<0.01）。两组ALT和AST平均值均较治疗前显著改善（P<0.01）。中药组治疗24周后ALB平均值显著高于治疗前（P<0.01）。
复方黄芪颗粒联合拉米夫定抗乙型肝炎病毒及改善肝功能的效果优于单纯使用复方黄芪颗粒。
